Pleiotropic effects of fibrates

被引：35

作者：

Chinetti-Gbaguidi G. ^{[1
]}

Fruchart J.C. ^{[1
]}

Staels B. ^{[1
]}

机构：

[1] UR 545 INSERM, Institut Pasteur de Lille, 59019 Lille

来源：

Current Atherosclerosis Reports | 2005年 / 7卷 / 5期

关键词：

Inflammatory Cytokine; Intervention Trial; Pleiotropic Effect; Combine Action; Phase Response;

D O I：

10.1007/s11883-005-0053-x

中图分类号：

学科分类号：

摘要：

Fibrates are a widely used class of hypolipidemic drugs. The effects of fibrates are mediated through the activation of the transcription factor peroxisome proliferator-activated receptor α (PPARα). Fibrates act to modulate the transcription of genes that encode proteins controlling lipid transport and metabolism. Fibrates also exert pleiotropic anti-inflammatory effects by downregulating expression of genes encoding inflammatory cytokines and acute phase response proteins. These combined actions translate into clinical benefit as demonstrated by the reduction in cardiovascular morbidity and mortality in primary and secondary intervention trials. Copyright © 2005 by Current Science Inc.

引用

页码：396 / 401

页数：5

共 58 条

[1] Barbier O., Torra I.P., Duguay Y., Et al., Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 22, pp. 717-726, (2002)
[2] Marx N., Sukhova G., Collins T., Et al., PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells, Circulation, 99, pp. 3125-3131, (1999)
[3] Delerive P., Martin-Nizard F., Chinetti G., Et al., PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway, Circ. Res., 85, pp. 394-402, (1999)
[4] Staels B., Koenig W., Habib A., Et al., Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators, Nature (London), 393, pp. 790-793, (1998)
[5] Chinetti G., Griglio S., Antonucci M., Et al., Activation of peroxisome proliferator-activated receptors a and g induces apoptosis of human monocyte-derived macrophages, J. Biol. Chem., 273, pp. 25573-25580, (1998)
[6] Chinetti G., Gbaguidi G.F., Griglio S., Et al., CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors, Circulation, 101, pp. 2411-2417, (2000)
[7] Dharancy S., Malapel M., Perlemuter G., Et al., Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection, Gastroenterology, 128, pp. 334-342, (2005)
[8] Blanquart C., Mansouri R., Fruchart J.C., Et al., Different ways to regulate the PPARalpha stability, Biochem. Biophys. Res. Commun., 319, pp. 663-670, (2004)
[9] Blanquart C., Barbier O., Fruchart J.C., Et al., Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes, J. Biol. Chem., 277, pp. 37254-37259, (2002)
[10] Blanquart C., Mansouri R., Paumelle R., Et al., The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha, Mol. Endocrinol., 18, pp. 1906-1918, (2004)

← 1 2 3 4 5 6 →